8-K current report · filed Oct 29, 2026

Gilead Sciences (GILD) 8-K Current Report: October 29, 2026

Item EX-99.1Item 2.02GILD overview

Short answer

Gilead Sciences (GILD) filed an 8-K current report with the SEC on October 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Gilead announced third-quarter 2026 results for the period ended September 30, 2026.

Gilead Sciences 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Gilead announced third-quarter 2026 results for the period ended September 30, 2026
  • Full financial results and GAAP-to-non-GAAP reconciliations available in Exhibit 99.1
  • Investors should distinguish management’s non-GAAP measures from GAAP results when assessing performance

Item EX-99.1 · Exhibit EX-99.1

  • Q3 product sales $8.3B, up 13%; excluding Veklury, sales rose 16% to $8.2B, showing strong underlying growth
  • HIV sales increased 18% to $6.2B, led by Biktarvy sales up 10% to $4.1B
  • Trodelvy sales rose 42% to $506M, while Cell Therapy sales fell 18% to $355M from competitive pressure
  • GAAP diluted EPS declined to $1.94 from $2.43, but non-GAAP EPS increased to $2.55 from $2.47
  • 2026 product-sales guidance raised to $31.0B-$31.3B, while full-year loss guidance worsened from $9.88B acquired IPR&D charges tied to acquisitions

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Gilead Sciences 8-K filings

Get the next GILD 8-K as it lands

Follow GILD for push alerts, or ask the research agent what this filing means.